Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
In conclusion LA is able
2022-05-24

In conclusion, LA is able to enhance osteoblast differentiation that mediated by PTH in a MCT-1 independent but GPR81 signaling dependent manner. This increase requires p38 activation and an Akt activation that depended on Gβγ-protein-PLC-PKC signaling. However, the ability of LA to increase PTH–med
-
br Results and discussion br
2022-05-23

Results and discussion Conclusion In this study the first binding assays based on a nonlabelled reporter ligand addressing GlyT1 are described. Following the concept of MS Binding Assays recently introduced in our group, binding of the well-known GlyT1 inhibitor Org24598 employed as reporter l
-
The translation of our rat findings to bovine and
2022-05-23

The translation of our rat findings to bovine and human lenses revealed that the expression of glucose transporters was more straightforward in bovine and human than in the rat lens, since only GLUT1 was detected in these lenses. Using the C-terminal GLUT1 antibody, we observed bands for GLUT1 in al
-
Our results revealed that when subjected to
2022-05-23

Our results revealed that when subjected to intravenous glucose tolerance tests, the RIP-Gcgr mice showed enhanced glucose tolerance and increased beta cell function, which is in agreement with the findings of Gelling et al. [6]. However, we also show that there is a reduced responsiveness of the be
-
Based on the collective experience to date it
2022-05-23

Based on the collective experience to date, it is likely that a much more comprehensive assessment of GSI selectivity for inhibition of multiple substrates, as well as biomarkers to track inhibition of non-APP substrates in vivo will be needed to support future efforts to develop substrate selective
-
Another small compound targeting IBAT has been evaluated
2022-05-23

Another small compound targeting IBAT has been evaluated in Phase I clinical trial (EudraCT 2013-001175-21) [86]. The oral administration of A4250 to healthy subjects did not give rise to any serious adverse events, was well tolerated and had a similar safety profile as elobixibat; however, it cause
-
Prion diseases are transmissible and result in fatal
2022-05-23

Prion diseases are transmissible and result in fatal neurodegenerative disorders, which, similar to AD, also involve the infiltration and activation of mononuclear phagocytes in Quercetin dihydrate lesions (reviewed in [61]). A 21 amino-acid fragment of the aberrant human prion protein, Prp106–126,
-
Hardy et al had demonstrated the role of
2022-05-23

Hardy et al. had demonstrated the role of GPR40 in mediating the proliferative effect of the FFA oleate's in breast cancer cells, and found that such effect can be reversed by silencing of GPR40 [14]. Similarly we have observed that inhibition of GPR40 function by its antagonist GW1100 inhibited cel
-
So what makes a FFAR
2022-05-23

So what makes a FFAR1 agonist different and interesting? As shown in the , the cellular mechanism is different from those of present insulin-releasing pharmacotherapies—namely the secretion initiators (sulphonylureas and meglitinides) and the incretin-based secretion potentiators (glucagon-like pept
-
br Other strategies for ferroptosis In addition to
2022-05-23

Other strategies for ferroptosis In addition to ROS-generating and GPX4 inactivating nanomaterials, small molecules and genetic manipulation targeting key factors in the ferroptosis pathway have also been tested for their anticancer effects [39,47,48]. Among a myriad of proteins involved in ferro
-
br Acknowledgements br Introduction Muscle FBPase is
2022-05-23

Acknowledgements Introduction Muscle FBPase is very sensitive to AMP inhibition and in the presence of physiological concentrations of this effector in muscle fibres FBPase should be almost completely inactive [1], [2]. Recently, we have presented evidence that, in vitro, muscle aldolase binds
-
We used a culture model of
2022-05-23

We used a culture model of human erythropoiesis that recapitulates all developmental stages [24] to screen a focused set of lncRNAs for potential contribution to this program. We found induction of lncRNA Fas-antisense 1 (Fas-AS1 or Saf) during RBC maturation and demonstrate that essential erythroid
-
Our results are consistent with the hypothesis that
2022-05-23

Our results are consistent with the hypothesis that reduced Fas-mediated apoptosis in maternally activated T-lymphocytes could result in insufficient trophoblast invasion of the spiral Genomic DNA Isolation Kit receptor as the activated T-lymphocytes become able to enhance the destruction of the cy
-
br Introduction The period around birth is a risky time
2022-05-23

Introduction The period around birth is a risky time for stroke in infants. Ischemic stroke has been diagnosed in about 1/4000 full-term infants (Nelson and Lynch, 2004) and perinatal stroke represents the second most frequent cause of acute seizures in this age group (Levy et al., 1985). Further
-
Interestingly hSMC displayed a similar
2022-05-23

Interestingly, hSMC displayed a similar morphological response to ET-1 as CHOETA. This dramatic lowering of normalized cell index in hSMC mimics ET-1 induced smooth muscle contraction. Earlier studies have shown that stress-fiber formations in CHOETA are mediated by Gq/PLC and G12 and in CHOETB by G
16372 records 450/1092 page Previous Next First page 上5页 446447448449450 下5页 Last page